唑来膦酸联合^89Sr治疗前列腺癌骨转移的临床疗效  

Clinical observation of zoledronic acid combined with ^89Sr in the treatment of prostate cancer patients with bone metastases

作　　者：李宁[1] 柴华[1] 杨志[1] 姚忠强[1] 杨鸿宇[1] 廖光星 肖国有[1] 李党生[1] 

机构地区：[1]广西医科大学附属肿瘤医院核医学科,南宁530021

出　　处：《国际放射医学核医学杂志》2017年第4期247-251,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：广西医疗卫生适宜技术开发与推广应用项目（S201633）;广西教育厅2016年中青年教师基础能力提升项目（KY2016LX025）;2014广西医科大学青年基金课题（GXMUYSF201408）

摘　　要：目的 评估唑来膦酸联合^89Sr治疗前列腺癌骨转移的临床疗效。方法 74例前列腺癌骨转移患者按简单随机分组方法分为3组：唑来膦酸联合^89Sr治疗组（A组）25例，年龄46-87岁，中位年龄66岁；单独给予唑来膦酸治疗组（B组）25例，年龄43-89岁，中位年龄65岁；单独给予^89Sr治疗组（C组）24例，年龄47-85岁，中位年龄66岁。其中，B组和C组为对照组。随访6个月，观察患者骨骼疼痛缓解情况和骨转移病灶数目改善情况。结果 3组患者的基线特征相似。治疗后，A组总的疼痛缓解率为88.0%，B组和C组分别为72.0%和79.2%，A组疼痛缓解情况与B组和C组相比差异有统计学意义（ χ^2=8.959，P〈0.05）。A组骨转移病灶好转率为88.0%，B组和C组分别为44.0%和75.0%，A组病灶好转情况分别与B组、C组相比，差异有统计学意义（χ^2=9.096，P〈0.05）。结论 唑来膦酸联合^89Sr治疗前列腺癌骨转移较单独给药具有更好的缓解疼痛作用，^89Sr治疗可有效减少骨转移病灶，提高患者的生活质量。Objective To evaluate the clinical curative effect of zoledronic acid combined with ^89Sr for the treatment of prostate cancer patients with bone metastases.Methods A total of 74 prostate cancer patients were randomly divided into three groups according to treatment,as follows：Group A （n=25;median age,66 years;age range,46-87 years）,zoledronic acid with ^89Sr;Group B （n=25;median age,65 years;age range,43-89 years）,zoledronic acid;and Group C （n=24;median age,66 years;age range,47-85 years）,^89Sr.Groups B and C were the control groups.All patients were followed up for 6 months,during which the status of bone pain relief and improvement in the number of bone metastatic lesions were observed.Results The three groups showed similar baseline characteristics.Total pain relief efficiency in group A was 88.0%,while those of the control groups were 72.0%（group B） and 79.2%（group C）.Pain palliation of group A significantly differed from those of groups B and C （χ^2=8.959,P〈0.05）.Regression of bone metastatic lesions in group A was 88.0%,while those of the control groups were 44.0%（group B） and 75.0%（group C）.Significant difference was found between group A and the two control groups （χ^2=9.096,P〈0.05）.Conclusion Combined therapy of zoledronic acid and ^89Sr in prostate cancer patients with painful bone metastases was more effective in treating pain and improving the quality of life than separate administration of zoledronic acid or ^89Sr.

关 键 词：前列腺肿瘤 锶放射性同位素 治疗效果 骨转移 唑来膦酸 

分 类 号：R737.25[医药卫生—肿瘤]